{
    "clinical_study": {
        "@rank": "149898", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Determine the bioavailability and biologic effect of alendronate on bone\n      metabolism in patients with cystic fibrosis.\n\n      II.  Assess the safety and efficacy of this treatment regimen in improving osteoporosis in\n      this patient population."
        }, 
        "brief_title": "Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis", 
        "condition": [
            "Osteoporosis", 
            "Cystic Fibrosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis", 
                "Osteoporosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double blind study. Patients will be stratified\n      according to sex (male vs female) and osteoporosis disease severity (mild vs severe).\n      Patients are randomized to one of two treatment arms.\n\n      Patients undergo bioavailability assessment to confirm the ability to absorb alendronate.\n\n      Arm I: Patients receive calcium and vitamin D supplements with a placebo daily for one\n      month.\n\n      Arm II: Patients receive calcium and vitamin D supplements with oral alendronate daily for\n      one month.\n\n      Treatment continues if differences are seen in bone mineral density between the treatment\n      arms.\n\n      Patients are followed for biochemical response at week 6, 12, and 52. Bone mineral density\n      is measured at 1 year and 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Diagnosis of cystic fibrosis Mild to moderate lung disease\n\n          -  At least one site specific (spine or femur) bone mineral density representing low\n             bone mass or osteopenia (greater than 1 standard deviation below peak bone mass)\n\n        --Prior/Concurrent Therapy--\n\n          -  Endocrine therapy: At least 3 months since prior corticosteroids\n\n        --Patient Characteristics--\n\n          -  Performance status: Ambulatory\n\n          -  Renal: Creatinine no greater than 3 mg/dL No renal failure\n\n          -  Other: No history of esophagitis No allergies to alendronate Not pregnant Fertile\n             female patients must use effective barrier contraception or progestin only oral\n             contraceptives (e.g., norethindrone) Ability to comply with treatment No intestinal\n             problems other than cystic fibrosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "60", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004489", 
            "org_study_id": "199/14270", 
            "secondary_id": "UNCCH-FDR001518"
        }, 
        "intervention": [
            {
                "intervention_name": "alendronate sodium", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "calcium carbonate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "cholecalciferol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcium Carbonate", 
                "Cholecalciferol", 
                "Alendronate"
            ]
        }, 
        "keyword": [
            "cardiovascular and respiratory diseases", 
            "cystic fibrosis", 
            "disease-related problem/condition", 
            "genetic diseases and dysmorphic syndromes", 
            "osteoporosis", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "contact": {
                "last_name": "Robert Aris", 
                "phone": "919-966-2531"
            }, 
            "facility": {
                "address": {
                    "city": "Chapel Hill", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27599-7070"
                }, 
                "name": "University of North Carolina School of Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "University of North Carolina", 
            "last_name": "Robert Aris", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004489"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "University of North Carolina", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "October 1998", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2000"
    }, 
    "geocoordinates": {
        "University of North Carolina School of Medicine": "35.913 -79.056"
    }
}